TRIUMPH-3 (NCT05882045) is a Phase 3, 80-week, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of retatrutide once weekly compared with placebo in participants with severe obesity (Class 2 or Class 3), defined as BMI 35 kg/m2, and established cardiovascular disease
Features liposomal glutathione for advanced daily support
Dec 30, 2025 You've acquired PT-141 (bremelanotide) for its unique libido-enhancing effects , but now face the practical challenge of actually using it correctly
GHK-Cu peptide therapy GHK-Cu Peptide Therapy in Connecticut: Skin Rejuvenation, Healing & Anti-Aging Benefits GHK-Cu peptide therapy supports skin health through collagen stimulation and tissue repair
Why should obesity be any less valid to treat than diabetes, these patients ask
References Committee on Mutual Recognition Agreements and Reliance in the Regulation of Medicines, Board on Global Health, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine